Literature DB >> 11170956

Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study.

D A Moore1, T Benepal, S Portsmouth, J Gill, B G Gazzard.   

Abstract

The objective of this prospective, observational study was to define the natural history of neutropenia in human immunodeficiency virus (HIV) disease. Eighty-seven consecutive patients developing neutropenia (absolute neutrophil count [ANC], <1000 cells/mm(3)) were recruited and closely followed for the duration of the episode. Episodes lasted a median of 13 days, with a mean ANC nadir of 660 cells/mm(3). Presumed or proven infection occurred in 12 (17%) of 71 evaluable subjects, and culture-proven infection occurred only in 6 (8%) of 71. Most of the episodes of neutropenia were brief, mild to moderate in nadir, and self-limiting without complications. Myelosuppressive therapies were implicated in almost all episodes. Serious infections occurred infrequently and were associated with low ANC nadirs but not with duration of the neutropenic episode. Low CD4(+) cell counts also increased the risk of infection complicating an episode of neutropenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170956     DOI: 10.1086/318495

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Authors:  George K Siberry; Paige L Williams; Jorge Lujan-Zilbermann; Meredith G Warshaw; Stephen A Spector; Michael D Decker; Barbara E Heckman; Emily F Demske; Jennifer S Read; Patrick Jean-Philippe; William Kabat; Sharon Nachman
Journal:  Pediatr Infect Dis J       Date:  2010-05       Impact factor: 2.129

2.  Effects of concurrent exposure to antiretrovirals and cotrimoxazole prophylaxis among HIV-exposed, uninfected infants.

Authors:  Alexander C Ewing; Caroline C King; Jeffrey B Wiener; Charles S Chasela; Michael G Hudgens; Debbie Kamwendo; Gerald Tegha; Mina C Hosseinipour; Denise J Jamieson; Charles Van der Horst; Athena P Kourtis
Journal:  AIDS       Date:  2017-11-28       Impact factor: 4.177

3.  Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

Authors:  Lawrence D Kaplan; Jeannette Y Lee; Richard F Ambinder; Joseph A Sparano; Ethel Cesarman; Amy Chadburn; Alexandra M Levine; David T Scadden
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

Review 4.  Neutropenia during HIV infection: adverse consequences and remedies.

Authors:  Xin Shi; Matthew D Sims; Michel M Hanna; Ming Xie; Peter G Gulick; Yong-Hui Zheng; Marc D Basson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2014-03-21       Impact factor: 5.311

5.  Systemic and mucosal mobilization of granulocyte subsets during lentiviral infection.

Authors:  Rhianna Jones; Cordelia Manickam; Daniel R Ram; Kyle Kroll; Brady Hueber; Griffin Woolley; Spandan V Shah; Scott Smith; Valerie Varner; R Keith Reeves
Journal:  Immunology       Date:  2021-06-16       Impact factor: 7.215

Review 6.  Invasive Aspergillus Sinusitis in Human Immunodeficiency Virus Infection: Case Report and Review of the Literature.

Authors:  John M Humphrey; Thomas J Walsh; Roy M Gulick
Journal:  Open Forum Infect Dis       Date:  2016-07-26       Impact factor: 3.835

7.  Incidence of Severe Neutropenia in HIV-Infected People Starting Antiretroviral Therapy in West Africa.

Authors:  Charline Leroi; Eric Balestre; Eugene Messou; Albert Minga; Adrien Sawadogo; Joseph Drabo; Moussa Maiga; Marcel Zannou; Moussa Seydi; Francois Dabis; Antoine Jaquet
Journal:  PLoS One       Date:  2017-01-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.